Search

Your search keyword '"ADC Therapeutics S.A. -- Forecasts and trends"' showing total 18 results

Search Constraints

Start Over You searched for: Descriptor "ADC Therapeutics S.A. -- Forecasts and trends" Remove constraint Descriptor: "ADC Therapeutics S.A. -- Forecasts and trends" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
18 results on '"ADC Therapeutics S.A. -- Forecasts and trends"'

Search Results

1. Waldenstrom Macroglobulinemia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | AbbVie, Cellectar Biosciences, TG Therapeutics, Eli Lilly and Company, Celgene Corp

2. Antibody-Drug Conjugates Market to Grow at 28.4% CAGR from 2024 to 2029

3. Antibody-Drug Conjugates Market to Grow at 28.4% CAGR from 2024 to 2029

4. Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market size is set to grow by USD 2.24 billion from 2024-2028, Growing geriatric population boost the market, Technavio

5. Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market size is set to grow by USD 2.24 billion from 2024-2028, Growing geriatric population boost the market, Technavio

6. Antibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 - Exclusive Study by The Insight Partners

7. Antibody Drug Conjugates (ADC) Market worth $19.8 billion | MarketsandMarkets

8. Antibody Drug Conjugates (ADC) Market worth $19.8 billion | MarketsandMarkets

9. Acute Lymphocytic Leukemia Market to Accelerate Substantially by 2032, Assesses DelveInsight | Key Companies in the Market - Beam, Pfizer, Genentech, AbbVie, Fate, Roche, Ascentage, Janssen, Jazz, ADC, Kymera, Syndax, ImmunoGen

10. Acute Lymphocytic Leukemia Market to Accelerate Substantially by 2032, Assesses DelveInsight | Key Companies in the Market - Beam, Pfizer, Genentech, AbbVie, Fate, Roche, Ascentage, Janssen, Jazz, ADC, Kymera, Syndax, ImmunoGen

11. 50+ Active Companies working to develop 50+ Pipeline Therapies for Relapsed Refractory Acute Myeloid Leukemia R R AML Treatment

12. Global Antibody Drug Conjugates (ADC) Markets, 2022-2028: Increasing Cases of Cancer with ADCs Showing to be a Substitute for Conventional Cancer Treatments Like Chemotherapy or Combination Therapy (Updated on September 15, 2022)

13. Global Antibody Drug Conjugates (ADC) Market Analysis Report 2022: A $13.8 Billion Market by 2028 - Increased Investments by Key Industry Players

14. Bladder Cancer Clinical Trial Pipeline Insights Featuring 100+ Companies | DelveInsight

15. Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Size to Grow by USD 1.79 billion, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio

16. The Global Antibody Drug Conjugates Market size is expected to reach $13.8 billion by 2028, rising at a market growth of 14.2% CAGR during the forecast period

17. The Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market is expected to grow by $ 1.79 bn during 2022-2026 progressing at a CAGR of 7.71% during the forecast period

18. Worldwide Antibody Drug Conjugates Industry to Register CAGR of 12.8% during 2021 - 2026

Catalog

Books, media, physical & digital resources